Latest news
Genfleet becomes first to test oral KRAS G12D inhibitor in Phase III for NSCLC - AllSciAllSci · Mon, 10 Aug 2026 10:33:20 GMTVerastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer - Yahoo FinanceYahoo Finance · Tue, 28 Jul 2026 07:00:00 GMT